Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Trading Up 4.4 %

Shares of NASDAQ CTSO opened at $0.94 on Friday. The stock has a market cap of $51.39 million, a P/E ratio of -2.61 and a beta of 0.57. The firm has a 50 day moving average price of $0.93 and a two-hundred day moving average price of $1.02. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.59.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently modified their holdings of the company. CM Management LLC lifted its holdings in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the period. Geode Capital Management LLC raised its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares in the last quarter. Atomi Financial Group Inc. acquired a new position in shares of Cytosorbents in the 3rd quarter valued at about $51,000. Finally, Sargent Investment Group LLC boosted its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.